Cyrill Wehling - Renal Disorders

Author Information

Cyrill Wehling is a researcher affiliated with the Department of Internal Medicine IV at the University Hospital of Heidelberg in Heidelberg. His work spans multiple fields with a focus on medical research, particularly in the areas related to liver diseases, renal disorders, and the application of complement system biomarkers.

Research Contributions

Cyrill Wehling has made significant contributions to the understanding and treatment of various disorders. His research includes the study of hepatocellular carcinoma, liver transplantation outcomes, and the management of Crohn’s disease and ulcerative colitis. Notably, his work also covers renal disorders with a focus on complement-mediated pathologies, as evidenced by his publications on complement activation biomarkers and their role in renal conditions. Wehling's research has provided insights into treatment strategies and patient quality of life, particularly in severe and treatment-refractory cases.

Aliases

Cyrill Wehling is also known in academic circles by the alias C. Wehling.

Publication and Citation Metrics

Metric	Value
Total Papers	14
Total Citations	263
H-index	8

Publications:

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

DOI: 10.1007/s00432-021-03528-3

Year: 2021

HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive liver-grafts to HBV-naïve recipients: A retrospective study.

DOI: 10.1016/j.clinre.2020.07.003

Year: 2021

Effects of realistic e-learning cases on students’ learning motivation during COVID-19

DOI: 10.1371/journal.pone.0249425

Year: 2021

Routine Liver Elastography Could Predict Actuarial Survival after Liver Transplantation.

DOI: 10.15403/jgld-218

Year: 2019

Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.

DOI: 10.3748/wjg.v25.i13.1603

Year: 2019

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

DOI: 10.3748/wjg.v25.i31.4481

Year: 2019

Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma

DOI: 10.1007/s00432-019-03005-y

Year: 2019

Monitoring of complement activation biomarkers and eculizumab in complement‐mediated renal disorders

DOI: 10.1111/cei.12890

Year: 2017

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

DOI: 10.1016/j.clim.2017.03.012

Year: 2017

Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.

DOI: 10.1093/ndt/gfw078

Year: 2016

How do NSAIDs affect the kidneys?

What Causes Nephrotic Syndrome?

What is Thromboembolism?

What is Interstitial Nephritis?

What is the Prognosis for PKD Patients?

Who Can Become a Living Donor?

Can diabetic nephropathy be prevented?

How Can Nephrotic Syndrome be Prevented?

When should a patient get a urine test?

Is Alcohol Safe for People with Pre-existing Kidney Conditions?

Partnered Content Networks

Relevant Topics